
Trastuzumab Deruxtecan Improves Survival in HER2+ Metastatic Gastric Cancer
Trastuzumab deruxtecan (Enhertu; T-DXd) exhibited a statistically significant and clinically meaningful improvement in overall survival (OS) vs ramucirumab (Cyramza) plus paclitaxel in patients with second-line HER2-positive unresectable or metastatic …